- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 89,660 | 27.06.24 19:47:18 | -1,220 | -1,34% | 0,000 | 0,000 | 90,210 | 90,880 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 993,000 | 27.06.24 08:12:54 | -13,500 | -1,34% | 0,000 | 0,000 | 993,000 | 1.006,500 |
